Overview

Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Status:
Recruiting

Trial end date:
2023-12-30

Target enrollment:

Participant gender:

Summary

TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination with nivolumab followed by FOLFIRI reintroduction, versus FOLFIRI as maintenance therapy in patients with advanced PDAC after induction therapy with FOLFIRINOX.

Phase:

Phase 2

Details

Lead Sponsor:

GERCOR - Multidisciplinary Oncology Cooperative Group

Collaborators:

Bristol-Myers Squibb
OSE Immunotherapeutics

Treatments:

Antibodies, Monoclonal
Fluorouracil
Irinotecan
Leucovorin
Nivolumab
Vaccines